These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 24919804)
61. Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells. Marzec M; Halasa K; Kasprzycka M; Wysocka M; Liu X; Tobias JW; Baldwin D; Zhang Q; Odum N; Rook AH; Wasik MA Cancer Res; 2008 Feb; 68(4):1083-91. PubMed ID: 18281483 [TBL] [Abstract][Full Text] [Related]
62. Clinical development of SRC tyrosine kinase inhibitors in lung cancer. Lee D; Gautschi O Clin Lung Cancer; 2006 May; 7(6):381-4. PubMed ID: 16800962 [TBL] [Abstract][Full Text] [Related]
63. Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth. Ke J; Chelvarajan RL; Sindhava V; Robertson DA; Lekakis L; Jennings CD; Bondada S Mol Cancer; 2009 Dec; 8():132. PubMed ID: 20043832 [TBL] [Abstract][Full Text] [Related]
64. Regulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway. Yang Z; Liao J; Carter-Cooper BA; Lapidus RG; Cullen KJ; Dan H BMC Cancer; 2019 May; 19(1):485. PubMed ID: 31118072 [TBL] [Abstract][Full Text] [Related]
65. Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis. Chan CM; Jing X; Pike LA; Zhou Q; Lim DJ; Sams SB; Lund GS; Sharma V; Haugen BR; Schweppe RE Clin Cancer Res; 2012 Jul; 18(13):3580-91. PubMed ID: 22586301 [TBL] [Abstract][Full Text] [Related]
66. Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines. Fallacara AL; Passannanti R; Mori M; Iovenitti G; Musumeci F; Greco C; Crespan E; Kissova M; Maga G; Tarantelli C; Spriano F; Gaudio E; Bertoni F; Botta M; Schenone S Eur J Med Chem; 2019 Nov; 181():111545. PubMed ID: 31400706 [TBL] [Abstract][Full Text] [Related]
67. Src: a potential target for the treatment of triple-negative breast cancer. Tryfonopoulos D; Walsh S; Collins DM; Flanagan L; Quinn C; Corkery B; McDermott EW; Evoy D; Pierce A; O'Donovan N; Crown J; Duffy MJ Ann Oncol; 2011 Oct; 22(10):2234-40. PubMed ID: 21357651 [TBL] [Abstract][Full Text] [Related]
68. Molecular profiling of TOX-deficient neoplastic cells in cutaneous T cell lymphoma. Xu J; Huang H; Wang S; Chen Y; Yin X; Zhang X; Zhang Y Arch Dermatol Res; 2020 Sep; 312(7):513-525. PubMed ID: 31676945 [TBL] [Abstract][Full Text] [Related]
69. Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A. Dargart JL; Fish K; Gordon LI; Longnecker R; Cen O Antiviral Res; 2012 Jul; 95(1):49-56. PubMed ID: 22609829 [TBL] [Abstract][Full Text] [Related]
70. miR-337 suppresses cutaneous T-cell lymphoma via the STAT3 pathway. Xia L; Wu L; Xia H; Bao J; Li Q; Chen X; Xia R Cell Cycle; 2019 Jul; 18(14):1635-1645. PubMed ID: 31213131 [TBL] [Abstract][Full Text] [Related]
71. MicroRNA-150 inhibits tumor invasion and metastasis by targeting the chemokine receptor CCR6, in advanced cutaneous T-cell lymphoma. Ito M; Teshima K; Ikeda S; Kitadate A; Watanabe A; Nara M; Yamashita J; Ohshima K; Sawada K; Tagawa H Blood; 2014 Mar; 123(10):1499-511. PubMed ID: 24385540 [TBL] [Abstract][Full Text] [Related]
72. Dasatinib induces a response in chronic lymphocytic leukemia. Pitini V; Arrigo C; Altavilla G Blood; 2009 Jan; 113(2):498. PubMed ID: 19131559 [No Abstract] [Full Text] [Related]
73. The role of Src family kinases in growth and migration of glioma stem cells. Han X; Zhang W; Yang X; Wheeler CG; Langford CP; Wu L; Filippova N; Friedman GK; Ding Q; Fathallah-Shaykh HM; Gillespie GY; Nabors LB Int J Oncol; 2014 Jul; 45(1):302-10. PubMed ID: 24819299 [TBL] [Abstract][Full Text] [Related]
74. NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib. Kießling MK; Nicolay JP; Schlör T; Klemke CD; Süss D; Krammer PH; Gülow K Oncotarget; 2017 Jul; 8(28):45687-45697. PubMed ID: 28537899 [TBL] [Abstract][Full Text] [Related]
75. Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells. Shi M; Lou B; Ji J; Shi H; Zhou C; Yu Y; Liu B; Zhu Z; Zhang J Cancer Chemother Pharmacol; 2013 Jul; 72(1):35-44. PubMed ID: 23712327 [TBL] [Abstract][Full Text] [Related]
76. Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-Negative Breast Cancer (TNBC) cells which overexpress Syndecan-Binding Protein (SDCBP). Qian XL; Zhang J; Li PZ; Lang RG; Li WD; Sun H; Liu FF; Guo XJ; Gu F; Fu L PLoS One; 2017; 12(1):e0171169. PubMed ID: 28141839 [TBL] [Abstract][Full Text] [Related]
77. Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib. Huang J; Hu W; Bottsford-Miller J; Liu T; Han HD; Zand B; Pradeep S; Roh JW; Thanapprapasr D; Dalton HJ; Pecot CV; Rupaimoole R; Lu C; Fellman B; Urbauer D; Kang Y; Jennings NB; Huang L; Deavers MT; Broaddus R; Coleman RL; Sood AK Clin Cancer Res; 2014 Apr; 20(7):1846-55. PubMed ID: 24486585 [TBL] [Abstract][Full Text] [Related]
78. Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia. Fei F; Stoddart S; Müschen M; Kim YM; Groffen J; Heisterkamp N Leukemia; 2010 Apr; 24(4):813-20. PubMed ID: 20111071 [TBL] [Abstract][Full Text] [Related]
79. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Nam S; Kim D; Cheng JQ; Zhang S; Lee JH; Buettner R; Mirosevich J; Lee FY; Jove R Cancer Res; 2005 Oct; 65(20):9185-9. PubMed ID: 16230377 [TBL] [Abstract][Full Text] [Related]
80. Malignant transformation of early lymphoid progenitors in mice expressing an activated Blk tyrosine kinase. Malek SN; Dordai DI; Reim J; Dintzis H; Desiderio S Proc Natl Acad Sci U S A; 1998 Jun; 95(13):7351-6. PubMed ID: 9636152 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]